It was a U.S. drugmaker that first alerted the FDA that the valsartan API it got from a Chinese ingredient maker contained a potentially dangerous impurity. And in the process of investigating, the ...
CD Formulation, a leading provider of analytical and formulation services, has recently announced the launch of its new Genotoxic Impurity (GI) Testing services. This innovative offering aims to ...
The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India. According to a translated copy of its announcement, Pfizer’s Tokyo-based Japanese subsidiary said it is ...
The Food and Drug Administration (FDA) has provided an update on its investigation into Valsartan HCTZ, a popular medication used to treat high blood pressure. The agency says tests on some of the ...
Mylan recalls three lots of nizatidine capsules, USP, due to detection of NDMA impurity found in API
Mylan N.V. announced that its US based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall, to the consumer level, of three lots of nizatidine capsules, USP (including the 150mg ...
Sustainability of small-molecule API manufacturing ensures continued success. Improving the sustainability of small-molecule API manufacturing is essential to ensuring the continued success of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback